CH50 as a putative biomarker of eculizumab treatment in neuromyelitis optica spectrum disorder

Here we report 3 cases of neuromyelitis optica spectrum disorder (NMOSD), who were all treated with eculizumab and could be observed with monitoring serum C3, C4 and 50% hemolytic complement (CH50) before and after the treatment. Serum C3 and C4 were not dramatically changed during the treatment, in...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Heliyon
Prif Awduron: Namatame, Chihiro, Misu, Tatsuro, Takai, Yoshiki, Nishiyama, Shuhei, Nakashima, Ichiro, Fujihara, Kazuo, Aoki, Masashi
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2021
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7809378/
https://ncbi.nlm.nih.gov/pubmed/33490671
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.heliyon.2021.e05899
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg